Sugi Predict

Sugi Predict / Compounds / SCHEMBL873911

SCHEMBL873911

SCHEMBL873911

CN(C)CCNC(=O)CCl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 2/20 0.55
▸ ALDH1A1 P00352 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ MAPK1 P28482 1/20 0.43
▸ LGALS1 P09382 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.41
▸ ACKR3 P25106 1/20 0.41
▸ PRMT3 O60678 1/20 0.40
▸ CARM1 Q86X55 1/20 0.40
▸ PRMT6 Q96LA8 1/20 0.40
▸ PRMT1 Q99873 1/20 0.40
▸ PRMT8 Q9NR22 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1612682 0.98 DNM1 (0.53) DNM1ALDH1A1SMN1; SMN2CA1CA2
SCHEMBL11026757 0.86 ALDH1A1 (0.60) DNM1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL13584322 0.83 DNM1 (0.57) DNM1ALDH1A1SMN1; SMN2CA1CA2
SCHEMBL1387314 0.81 DNM1 (0.55) DNM1ALDH1A1SMN1; SMN2CA1CA2
SCHEMBL1387313 0.81 DNM1 (0.55) DNM1ALDH1A1SMN1; SMN2CA1CA2
SCHEMBL1456344 0.81 DNM1 (0.60) DNM1ALDH1A1CA1CA2CA12
SCHEMBL47678 0.81 DNM1 (0.60) DNM1ALDH1A1CA1CA2CA12
SCHEMBL7402671 0.80 ALDH1A1 (0.56) DNM1ALDH1A1SMN1; SMN2CA1CA2
SCHEMBL7046018 0.80 ALDH1A1 (0.56) DNM1ALDH1A1SMN1; SMN2CA1CA2
SCHEMBL24754677 0.79 DNM1 (0.63) DNM1ALDH1A1SMN1; SMN2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12594274-B2 Method for preparing a crystalline form of rabeximod Gulch Pharma AB (SE) 2026-04-07 — — US claimed
EP-4165043-A1 METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD Cyxone AB (SE) 2023-04-19 — — EP claimed
CN-115698010-A Process for preparing a crystalline form of RABEXIMOD 赛克松公司 2023-02-03 — — CN claimed
US-20230227456-A1 ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMOD CYXONE AB (SE) 2023-07-20 — — US disclosed
US-20230227455-A1 METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD CYXONE AB (SE) 2023-07-20 — — US disclosed
US-20230227455-A1 METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD CYXONE AB (SE) 2023-07-20 — — US disclosed
EP-4165043-A1 METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD Cyxone AB (SE) 2023-04-19 — — EP disclosed
CN-115698010-A Process for preparing a crystalline form of RABEXIMOD 赛克松公司 2023-02-03 — — CN disclosed
US-20220133717-A1 RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS CYXONE AB (SE) 2022-05-05 — — US disclosed
WO-2021250199-A1 RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS CYXONE AB (SE) 2021-12-16 — — WO disclosed
WO-2021250197-A1 METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD CYXONE AB (SE) 2021-12-16 — — WO disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
CN-101208094-A Pharmacokinetic improved compounds SURFACE LOGIX INC (US) 2008-06-25 — — CN disclosed
WO-2008054599-A2 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2008-05-08 — — WO disclosed
WO-2008054599-A2 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2008-05-08 — — WO disclosed
EP-1865958-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS Surface Logix, Inc. (US) 2007-12-19 — — EP disclosed
WO-2006105081-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2006-10-05 — — WO disclosed
EP-0040793-B1 NOVEL QUINAZOLINE-DIONE COMPOUNDS, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF Ishikawa, Masayuki (JP) 1985-08-28 — — EP disclosed
US-4405623-A HYPOTENSIVE AGENTS, VASODILATORS MASAYUKI ISHIKAWA (JP) 1983-09-20 — — US disclosed
EP-0040793-A1 Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof Ishikawa, Masayuki (JP) 1981-12-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227455-A1 METHOD FOR PREPARING A CRYSTALLINE FORM OF RABEXIMOD RAB2A, RAB9A, RAB10 DNM1 31/4885ALDH1A1 3008/4885SMN1; SMN2 3967/4885
US-20230227456-A1 ORAL FORMULATION COMPRISING A CRYSTALLINE FORM OF RABEXIMOD RAB8A, RAB1A, RAB10 DNM1 168/4885ALDH1A1 2205/4885SMN1; SMN2 2773/4885
US-12594274-B2 Method for preparing a crystalline form of rabeximod RAB10, RAB9A, RAB1A DNM1 194/4885ALDH1A1 954/4885SMN1; SMN2 2476/4885
US-20220133717-A1 RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS RAB10, RAB2A, RAB1A DNM1 101/4885ALDH1A1 1759/4885SMN1; SMN2 4001/4885
US-20100144707-A1 Pharmacokinetically improved compounds ROCK2, ROCK1, RHOT2 DNM1 27/4885ALDH1A1 2225/4885SMN1; SMN2 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.